News - Tyverb

Filter

Current filters:

Tyverb

Popular Filters

GlaxoSmithKline's Tykerb/Tyverb and chemotherapy combo fails in gastric cancer

04-06-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) says that its study of Tykerb/Tyverb (lapatinib) in combination…

GlaxoSmithKlineOncologyPharmaceuticalResearchTykerbTyverb

GlaxoSmithKline files for Tykerb/Tyverb with trastuzumab in USA and Europe

17-02-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday that it has submitted regulatory applications…

EuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationtrastuzumabTykerbTyverb

GSK and Novartis withdraw EU extended use applications for Tyverb and Fluad, respectively

16-02-2012

The European Medicines Agency has been formally notified by UK pharma giant GlaxoSmithKline (LSE: GSK)…

EuropeFluadGlaxoSmithKlineNovartisOncologyPharmaceuticalRegulationTyverbVaccines

NICE views breast cancer drugs from GSK and Roche too expensive

14-02-2012

The UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

EuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

UK NICE says benefits of breast cancer drugs Tyverb and Herceptin still unproven

03-07-2011

In a draft guidance issued last Friday, the UK’s drug watchdog, the National Institute for Health…

GlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRegulationRocheTyverb

Company Spotlight

Fibrotech

Fibrotech

Back to top